Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.55 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.51 |
| ▸ | WNT3A | P56704 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1016601 | 1.00 | CES2 (0.57) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL29601127 | 0.98 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL504833 | 0.98 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL6833226 | 0.96 | CES2 (0.57) | CES2CES1GRM4L3MBTL1LMNA | |
| Bromide SCHEMBL5121089 | 0.94 | CES2 (0.55) | CES2CES1GRM4L3MBTL1LMNA | |
| Pyridine SCHEMBL8599632 | 0.91 | L3MBTL1 (0.55) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL12777709 | 0.82 | CES2 (0.59) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL2470002 | 0.81 | CTNNB1 (0.71) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL253276 | 0.81 | CES2 (0.64) | CES2CES1GRM4L3MBTL1LMNA | |
| SCHEMBL29355245 | 0.81 | CES2 (0.64) | CES2CES1GRM4L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021943-A1 | QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NEURALIS (BE) | 2025-01-30 | — | — | WO | disclosed |
| CN-118284604-A | Fused heterocycles as RIPK1 inhibitors | 比西切姆有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| CN-117343081-A | MAT2A inhibitor, pharmaceutical composition and application thereof | 南京正大天晴制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| CN-114787135-A | Substituted imidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | CES2 2297/4885CES1 1862/4885GRM4 3746/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | CES2 4390/4885CES1 3166/4885GRM4 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.